Overview of the Investigation
In recent news, attorney firm Johnson Fistel, PLLP has launched an investigation into Soleno Therapeutics, Inc. (NASDAQ: SLNO). This inquiry focuses on whether the company and some of its officers and directors breached federal securities laws. The allegations center around making false or misleading statements while failing to disclose critical information to investors.
Commercial Progress of VYKAT™ XR
In particular, the investigation seeks to determine if Soleno's communications accurately depicted the commercial progress and safety profile of their recently approved product, VYKAT™ XR. Following its FDA clearance in September 2025, Soleno assured investors about the strong performance and positive rollout of this new treatment.
Launch Challenges and Adjustments
However, during a third-quarter earnings call on November 4, 2025, Soleno disclosed emerging challenges related to the launch of VYKAT™ XR. The company reported a decrease in new treatment initiations and noted an increase in therapy discontinuations linked to non-serious adverse events. Management acknowledged that these challenges were influenced by external commentary made earlier in the year, highlighting the complexities involved in bringing a new product to market.
Concerns Raised by Scorpion Capital
On August 15, 2025, Scorpion Capital released a report that raised serious concerns regarding VYKAT™ XR and Soleno's marketing strategies. The report pointed out potential safety issues, questioned the sustainability of demand for the product, and expressed concerns over the level of early prescribing activity. Scorpion Capital also critiqued Soleno's business model for being overly dependent on a single product, hinting that its intellectual property would soon face challenges as it neared expiration.
Impact on Stock Price
Following the release of the critical report, Soleno's stock price faced notable fluctuations. From August 14, 2025, to November 5, 2025, the share price plunged almost 40%. This dramatic decline has left many investors anxious about their investments in SLNO.
What Should Investors Do?
For those who bought shares of Soleno Therapeutics and are now grappling with losses, it's essential to stay informed and consider joining the investigation led by Johnson Fistel, PLLP. This investigation aims to provide clarity and assess whether you have a valid claim for your investments.
Investors in SLNO should weigh their options carefully. Engaging with legal experts may help in understanding the potential ramifications and what steps to take next. Gathering all necessary documentation and records related to your investments will be vital.
Contact Information for Assistance
If you are interested in participating in the investigation, reach out to Johnson Fistel for more information. You can contact Jim Baker at (619) 814-4471 or email him directly. There is no upfront cost, and the firm is committed to protecting investors' rights.
About Johnson Fistel, PLLP
Johnson Fistel, PLLP is a well-regarded law firm specializing in shareholder rights and has established offices across several states. The firm helps both individuals and institutional investors navigate securities class actions and derivative lawsuits. They also offer their expertise to international investors engaged in the U.S. markets.
In 2024, the firm was recognized among the Top 10 Plaintiff Law Firms, recovering approximately $90 million for investors in successful cases. Their continuous recognition underscores their commitment to serving investors effectively.
Frequently Asked Questions
What triggered the investigation into Soleno Therapeutics?
The investigation was initiated due to concerns that Soleno and its executives might have violated securities laws by misleading investors regarding the VYKAT™ XR product.
How did the FDA's approval of VYKAT™ XR affect Soleno's stock?
While the initial approval was seen as a positive step, subsequent challenges during the product rollout led to a substantial decline in Soleno's stock price.
What should investors do if they incurred losses with SLNO?
Investors should consider participating in the investigation by contacting legal representatives from Johnson Fistel for guidance.
What were the main concerns highlighted in the Scorpion Capital report?
The report raised questions about the safety of VYKAT™ XR, the viability of demand for the product, and the sustainability of Soleno's business model.
How can investors contact Johnson Fistel for more information?
Interested investors can reach Jim Baker at (619) 814-4471, or email for further assistance.
